Royalty Report: Drugs, Genome, Drug Discovery – Collection: 282952

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5

Primary Industries

  • Drugs
  • Genome
  • Drug Discovery
  • cell therapy
  • Tissue
  • Antibody
  • Therapeutic
  • Cancer
  • Proteins
  • Biotechnology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 282952

License Grant
The Universities grant a license in the Licensed Field of Use to make, use, and sell Licensed Product in the Licensed Territory and to use Invention and Licensed Materials.
License Property
A University has an assignment of WNT Compositions and Methods.  The WNT Compositions and Methods patent, involves the use of a gene that is active in the growth and development of tissues and cells.

Wnt is a key developmental pathway that affects the expression of multiple target genes.

Licensed Materials means proprietary materials of either University which are developed by either University as a result of research concerning the Licensed Invention.

Field of Use
Licensee focuses on translating developmental biology insights into therapies that will significantly improve the quality of life by activating the body's ability to repair and regenerate, or to specifically control abnormal or malignant growth.

IPSCIO Record ID: 328113

License Grant
The Universities grants a license in the Licensed Field of Use to make, use, and sell Licensed Product in the Licensed Territory and to use Invention and Licensed Materials. Said license is Exclusive, including the right to sublicense in the Licensed Field of Use.
License Property
The Licensed Patent means U.S. Patent Application, Serial Number 832,340.

Licensors each have an assignment of WNT Compositions and Methods, collectively the invention, which involves the use of a gene that is active in the growth and development of tissues and cells.

Field of Use
Licensee focuses on translating developmental biology insights into therapies that will significantly improve the quality of life by activating the body's ability to repair and regenerate, or to specifically control abnormal or malignant growth.

IPSCIO Record ID: 203513

License Grant
The University grants a worldwide license, under the patent rights to make and have made, to use and have used, to sell and have sold the Products for the life of the patent rights, and a worldwide license to use Biological Materials to make and have made, to use and have used, to sell and have sold or to identify the Milestone Products. Such license shall include the right to grant sublicenses. Licensor grants the right to assign the licenses granted or to be granted.  This agreement has an exclusive period.
License Property
The Licensed products shall mean products, the manufacture, use or sale of which would, absent the license granted hereunder, infringe a Claim, with the exception of any antibodies which bind to a hedgehog protein which shall be designated as Milestone Products.

Biological Materials shall mean the proprietary materials developed in the laboratories of certain Drs. as a result of research concerning the licensed subject matter, identified including Polypepetides, Gene Sonic hedgehog (shh), Gene Indian hedgehog (lhh) and Gene Desert hedgehog (Dhh), together with any progeny, mutants or derivatives, to the extent that they contain a substantial portion of the original Biological Materials. Proprietary materials shall mean materials which are not generally available from another source and which are under the control of Licensor.

Sonic hedgehog is a protein that in humans is encoded by the SHH ('sonic hedgehog') gene. Both the gene and the protein may also be found notated alternatively as 'Shh'.Sonic hedgehog is one of three proteins in the mammalian signaling pathway family called hedgehog, the others being desert hedgehog (DHH) and Indian hedgehog (IHH). SHH is the best studied ligand of the hedgehog signaling pathway. It plays a key role in regulating vertebrate organogenesis, such as in the growth of digits on limbs and organization of the brain.

Milestone Products shall mean products which are not Licensed Products and are identified or discovered in material part through the use of processes or subject matter covered in a Claim or agonize or antagonize members of the hedgehog gene family or agonize or antagonize follistatin or incorporate a substantial portion of a Biological Material or which could not be made except by utilizing a Biological Material or are antibodies which bind to a hedgehog protein.

PATENT RIGHTS shall mean United States patent application Serial No. 08/136.748 filed October 14. 1993 and United States patent application Serial No. 08/176.427 filed December 30. 1993. United States Patent Application Serial No. 09/394.020. filed September 10,1999.

Field of Use
The Licensee is a therapeutic drug development company principally focused on the discovery, development and future commercialization of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs.

IPSCIO Record ID: 289171

License Grant
The University grants a license under the Licensed Patents in the Licensed Field of Use to make, have made, use, have used, sell, have sold, offer to sell, have offered to sell, lease, have leased, import and have imported Licensed Products in the Licensed Territory.   The license is Exclusive.
License Property
The license is for patents and an invention named Wnt Compositions and Methods of Use Thereof.  Wnt refers to proteins.

Licensed Product means any device, composition, product or part of a product in the Licensed Field of Use, the manufacture, use, sale, offer for sale or import of which, but for the licenses granted herein, would infringe a Valid Claim of a Licensed Patent.

Field of Use
Licensee has identified Wnt7a, a naturally-occurring secreted protein, as a key regulator of skeletal muscle regeneration.

IPSCIO Record ID: 352695

License Grant
University grants an exclusive, worldwide license in the Patent Rights to make, have made, use, offer for sale, sell, have sold and import Licensed Products in the Field.
License Property
The patents include
–  Allele-specific RNA Interference;
–  In Vivo Production of Small Interfering RN As that Mediate Gene Silencing;
–  RNA Interference for the Treatment of Gain-of-Function Disorders;
–  Novel AAVs and Uses Thereof;
–  CNS Targeting AAV Vectors and Methods of Use Thereof;
–  Methods and Compositions for Controlling Efficacy of RNA Silencing;
–  Methods and Compositions for Enhancing the Efficacy and Specificity of Single and Double Blunt-Ended siRNA; and,
–  Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi.
Field of Use
The Field of use is the treatment of human diseases using gene therapy applications.  Any commercial sale of research reagents covered by the Patent Rights is specifically excluded
from the Field.

The gene therapy approach uses AAV (adeno-associated virus) vectors, which are modified, non-replicating versions of AAV, and which we believe are ideal vectors for CNS gene therapy.

The Licensee expects to utilize established and novel techniques for dosing and delivery of our AAV gene therapies to the CNS.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.